Icro Medical Technologies

Icro Medical Technologies
Name	Icro Medical Technologies
Type	Private
Industry	Medical devices
Founded	2011
Founder	Giovanni Riva
Headquarters	Bologna, Italy
Key people	Giovanni Riva (CEO)
Products	Hemostasis devices, surgical instruments
Employees	120 (2024)

Icro Medical Technologies is an Italian medical device company specializing in surgical hemostasis and minimally invasive instruments. Founded in 2011 in Bologna, the firm develops electrosurgical and mechanical solutions used in hospitals and clinics across Europe and select international markets. Icro collaborates with academic hospitals and research institutions to translate surgical techniques into commercial devices.

History

Founded in 2011 by Giovanni Riva in Bologna, Icro Medical Technologies emerged from collaborations with clinicians at the University of Bologna and engineers from the Italian Institute of Technology. Early pilot studies involved teams from Policlinico Sant'Orsola-Malpighi and innovators linked to the European Society of Cardiology. The company participated in programs with Centro Nazionale delle Ricerche and received seed funding involving investors connected to European Investment Bank initiatives. Icro expanded its R&D footprint through partnerships with university hospitals such as Karolinska University Hospital, Charité – Universitätsmedizin Berlin, and Mayo Clinic collaborators on translational studies. The firm showcased devices at trade events including Medica (trade fair), Arab Health, and RSNA Annual Meeting, and engaged with standards bodies like ISO committees and European Committee for Standardization. Strategic growth phases involved alliances with distributors linked to B. Braun Melsungen AG, Medtronic, and regional partners resembling Getinge AB networks.

Products and Services

Icro’s product range centers on mechanical and energy-based hemostasis devices designed for laparoscopic, open, and endoscopic surgery. Flagship offerings include single-use vessel sealing instruments, reusable handles, and bipolar electrosurgical generators. The company supplies hospitals, surgical centers, and research labs, providing training programs delivered alongside teams from Cleveland Clinic and Johns Hopkins Hospital. Service lines include product customization for institutions such as Massachusetts General Hospital and maintenance contracts aligned with procurement practices at entities like National Health Service (England). Commercial activities are supported by participation in purchasing frameworks similar to Group Purchasing Organization (GPO) models and tender processes used by organizations like Karolinska University Hospital and AP-HP.

Technology and Research

Icro invests in materials science, electrosurgery, and device ergonomics, collaborating with laboratories at the Scuola Superiore Sant'Anna, Imperial College London, and ETH Zurich. Research themes include bipolar energy modulation, thermal spread reduction, and polymeric sealants informed by work at Max Planck Society spin-offs and protocols developed at Cleveland Clinic Lerner Research Institute. Preclinical testing occurred in animal facilities associated with Istituto Zooprofilattico Sperimentale guidelines and followed standards common to trials at Food and Drug Administration-regulated centers and European Medicines Agency-linked programs. Icro-sponsored publications have been presented at conferences such as American College of Surgeons Clinical Congress and European Association for Endoscopic Surgery meetings, and researchers have collaborated with investigators affiliated with Harvard Medical School, Stanford University School of Medicine, and University of Oxford.

Regulatory Approvals and Compliance

Icro’s devices comply with CE marking requirements and harmonized standards applied across the European Union. Regulatory engagement has involved notified bodies similar to BSI Group and conformity assessments reflecting directives adopted in frameworks used by European Commission authorities. For markets outside Europe, submissions have been prepared for pathways modeled on U.S. Food and Drug Administration 510(k) clearance processes and regulatory frameworks of agencies such as Health Canada and the Therapeutic Goods Administration. Quality systems adhere to standards like ISO 13485 and documentation practices paralleling those at corporations such as Stryker Corporation and Zimmer Biomet.

Corporate Structure and Ownership

Icro operates as a privately held company headquartered in Bologna with a management team experienced in entrepreneurship and clinical engineering. Governance includes a board comprising investors and clinicians with affiliations to institutions like University of Milan, Bocconi University, and Politecnico di Milano. Funding rounds have included venture investors and grants from entities comparable to Horizon 2020 programs and regional development agencies tied to Emilia-Romagna Region economic initiatives. Partnerships with distribution companies mirror structures seen in collaborations between Coloplast and regional distributors in Germany, France, and United Kingdom markets.

Clinical Applications and Partnerships

Clinical deployment focuses on vascular control in procedures performed at centers including Guy's and St Thomas' NHS Foundation Trust, Royal Melbourne Hospital, and Ospedale San Raffaele. Icro engaged surgeon advisors from specialties represented by societies such as American College of Surgeons, European Society for Vascular Surgery, and International Hepato-Pancreato-Biliary Association. Collaborative clinical studies and investigator-initiated trials have been run with teams linked to Mayo Clinic, Utrecht University Medical Center, and Hospital Clínic de Barcelona, evaluating outcomes in colorectal, hepatobiliary, and gynecologic surgery.

Market Presence and Financial Performance

Icro sells into European and select international markets through distributor networks and direct hospital contracts. Market channels mirror approaches used by mid-sized medtech firms such as ConMed Corporation and Becton, Dickinson and Company for product rollout. Financial performance is characterized by private reporting; growth indicators include successive commercial expansions and participation in procurement tenders at institutions like Karolinska University Hospital and University College London Hospitals NHS Foundation Trust. Revenue and employee metrics are tracked internally and reported to investors in funding rounds influenced by regional venture ecosystems similar to those around Start-Up Nation Central and Italian Investment Fund initiatives.

Category:Medical device companies